Challenges and Emerging Solutions to Management of Type 2 Diabetes: A Personalized Educational Curriculum
| Title: | Challenges and Emerging Solutions to Management of Type 2 Diabetes: A Personalized Educational Curriculum |
| Topic: | Diabetology |
| Relevant Terms: | Diabetes, Diabetes Treatment, SGLT-2 |
| Primary Audience: | Primary Care Physicians; Nurse Practitioners and other health care professionals treating diabetic patients |
| Launch Date: | 15-Nov-11 |
| Credits: | 1 AMA PRA Category 1 Credit™ |
| Expiration Date: | 14-Nov-12 |
| Curriculum Name: | Challenges and Emerging Solutions to Management of Type 2 Diabetes: A Personalized Educational... |
Learning Objectives
After completing this activity, the participant will demonstrate the ability to:
- Outline current algorithm recommendations for type 2 diabetes management from two writing groups: one assembled by AACE/ACE and another by the ADA/EASD.
- Describe the characteristics and physiologic functions of the renal sodium-glucose co-transport proteins
- Outline the mechanism of action of SGLT-2 inhibitors and discuss its therapeutic potential to address current unmet needs in the treatment of type 2 diabetes
- Summarize the efficacy, safety, and tolerability of emerging SGLT-2 inhibitors and assess their potential role in the treatment of type 2 diabetes
Faculty
Lawrence Blonde, MD, FACP, FACE
Director, Ochsner Diabetes Clinical Research Unit
Department of Endocrinology, Diabetes, and Metabolic Diseases
Ochsner Medical Center
New Orleans, Louisiana
Director, Ochsner Diabetes Clinical Research Unit
Department of Endocrinology, Diabetes, and Metabolic Diseases
Ochsner Medical Center
New Orleans, Louisiana
pmiCME Clinical Staff, University of Wisconsin School of Medicine and Public Health and Tufts Health Care Institute Expert Peer Reviewers Financial Disclosure
The content collaborators and planning committee at pmiCME include Marc Mosier, MD, Marissa Seligman, PharmD, Alyce Kuklinski, NP, Zachary Schwartz, MSc, ELS, Kashemi Rorie, PhD, and Christopher Drury, MA, have no financial relationships to disclose. Carolyn Skowronski, PharmD, has disclosed that she owns stock in Merck.
The content collaborators and planning committee at pmiCME include Marc Mosier, MD, Marissa Seligman, PharmD, Alyce Kuklinski, NP, Zachary Schwartz, MSc, ELS, Kashemi Rorie, PhD, and Christopher Drury, MA, have no financial relationships to disclose. Carolyn Skowronski, PharmD, has disclosed that she owns stock in Merck.
pmiCME Disclosure Policy
It is the policy of pmiCME to ensure balance, independence, objectivity and scientific rigor in all its sponsored educational programs. All faculty participating in the sponsored programs are expected to disclose to the program audiences any real or apparent conflict(s) of interest related to the content of their presentation(s).
It is the policy of pmiCME to ensure balance, independence, objectivity and scientific rigor in all its sponsored educational programs. All faculty participating in the sponsored programs are expected to disclose to the program audiences any real or apparent conflict(s) of interest related to the content of their presentation(s).
Medical and Nursing Advisory Board Financial Disclosure
George Mejicano, MD, and Victor Diaz, MD, have nothing to disclose.
Michael J. Bloch, MD, is a consultant and member of the speaker's bureaus for AstraZeneca Pharmaceuticals LP, and Takeda. He also serves on the speaker's bureau for Abbott Laboratories and Boehringer Ingelheim. Frances Medaglia, PhD, RN, NP; Nancy Boccozzi. RN, MA, MPH; and Cathy St. Pierre, PhD, ARNP, have nothing to disclose.
George Mejicano, MD, and Victor Diaz, MD, have nothing to disclose.
Michael J. Bloch, MD, is a consultant and member of the speaker's bureaus for AstraZeneca Pharmaceuticals LP, and Takeda. He also serves on the speaker's bureau for Abbott Laboratories and Boehringer Ingelheim. Frances Medaglia, PhD, RN, NP; Nancy Boccozzi. RN, MA, MPH; and Cathy St. Pierre, PhD, ARNP, have nothing to disclose.
Education Partner Financial Disclosure Statement
The content collaborators and planning committee at Horizon CME include Brian Lee, PharmD; Elizabeth Hill, CHES; and Cara Williams, PharmD. Brian Lee, PharmD, and Elizabeth Hill, CHES, have nothing to disclose. The spouse of Cara Williams, PharmD, has an active clinical research grant with Merck.
The content collaborators and planning committee at Horizon CME include Brian Lee, PharmD; Elizabeth Hill, CHES; and Cara Williams, PharmD. Brian Lee, PharmD, and Elizabeth Hill, CHES, have nothing to disclose. The spouse of Cara Williams, PharmD, has an active clinical research grant with Merck.
Faculty Financial Disclosures
Dr. Blonde has served as an investigator for Boehringer-Ingelheim Pharmaceuticals, Inc., Eli Lilly and Company, Johnson & Johnson, Novo Nordisk, Roche, and sanofi-aventis, U.S.; as a speaker for AstraZeneca, Boehringer-Ingelheim Pharmaceuticals, Inc., Bristol-Myers Squibb, Daiichi Sankyo, Merck & Co., Inc., Novo Nordisk, Santarus, Vero Science; and as a consultant for Amylin Pharmaceuticals, Inc., AstraZeneca, Boehringer-Ingelheim Pharmaceuticals, Inc., Bristol-Myers Squibb, Daiichi Sankyo, GlaxoSmithKline, Halozyme, Johnson & Johnson, Mannkind Corporation, Merck & Co., Inc., Novo Nordisk, Orexigen Therapeutics, Roche, sanofi-aventis, U.S., Santarus, and Vero Science. Dr. Blonde's late spouse's estate contains shares of Amylin Pharmaceuticals and Pfizer, Inc.
DISCLOSURE ATTESTATION
As a continuing medical education provider accredited by the ACCME, it is the policy of pmiCME to require any individual in a position to influence educational content to disclose the existence of any financial interest or other personal relationship with the manufacturer(s) of any commercial product(s).
DISCLAIMER
The opinions, ideas, and recommendations expressed in this educational activity are those of the faculty only and are not necessarily endorsed, nor do they necessarily reflect, those of their affiliated institutions, pmiCME, pmiCME Advisory Boards and Consultants, or DBC Pri-med, LLC.
Clinical judgment must guide each clinician in weighing the possible risks, benefits, or contraindications of any diagnostics, interventions or treatments discussed. Clinicians should review manufacturers' product information and consider these with the recommendations of other authorities when applying the assessment and/or clinical management strategies discussed in this activity to the care of their patients.
COMMERCIAL SUPPORT
This activity is supported by an educational grant from Bristol-Myers Squibb and AstraZeneca Pharmaceuticals LP, Alliance Partners
ACCREDITATION STATEMENT
pmiCME is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
DESIGNATION STATEMENT
pmiCME designates this enduring material activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
HOW TO RECEIVE CREDIT
By reviewing the course content and successfully completing the post-test and evaluation, physicians are entitled to receive 1 AMA PRA category 1 credits™. Statement of credit will be available to print from your user history page.
- Read the learning objectives and faculty disclosures.
- Participate in the activity.
- Complete the post-test and activity evaluation.
- All other participants who successfully complete the post-test and evaluation will receive a certificate of participation.
Additional Accreditation Information
Purpose Statement:
The purpose of Pri-Med Online is to provide primary care clinicians with timely, evidence-based information for current or future applications in patient care.
Investigational Disclosure:
In accordance with pmiCME policy, faculty have been asked to disclose discussion of unlabeled or unapproved use(s) of drugs or devices within this activity. Any mention of unlabeled or unapproved uses(s) is indicated in the content. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Statement of Independence:
pmiCME educational activities are developed and conducted in accordance with the ACCME's Essential Areas and Policies. It is the mission of pmiCME to develop and present educational activities that are timely, fair-balanced, scientifically rigorous, and that serve to improve patient outcomes. To that end, we welcome your comments about how to better serve your needs.
Conflict of Interest Resolution:
When faculty have reported Financial Relationships with one or more commercial interests, pmiCME works with the faculty to resolve such conflicts to ensure that the content presented is free of commercial bias and that it promotes improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest. The content of this presentation was vetted by the following mechanisms and modified as required to meet this standard:
— Content Peer Review by external topic Expert
— Content Validation by external topic Expert and internal pmiCME clinical editorial staff
— Content Peer Review by external topic Expert
— Content Validation by external topic Expert and internal pmiCME clinical editorial staff
